Skip to content

Ocular effect of TRPM8 agonist in patients with dry eye disease

Effect of topical administration of TRPM8 agonist in patients with dry eye disease: a single-center randomized double-masked vehicle-controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN24802609
Enrollment
60
Registered
2015-03-21
Start date
2015-01-09
Completion date
Unknown
Last updated
2020-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye is a disorder of the tear film due to tear deficiency or excessive evaporation, which causes damage to the interpalpebral ocular surface and is associated with symptoms of ocular discomfort. Eye Diseases Other disorders of lacrimal gland

Interventions

TRPM8 agonist (1-(Diisopropyl-phosphinoyl)-nonane) dissolved in distilled water (2 mg/mL) or vehicle (distilled water) was topically delivered using the absorbent cotton gauze square (0.4 g rectangle

Sponsors

Chonnam National University Medical School and Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Dry eye symptoms for more than 3 months despite the use of artificial tears 2. Low tear film break-up time (TBUT) (= 7 seconds) 3. Low Schirmer score (= 10 mm/5 min) 4. Presence of corneal and conjunctival epithelial damage

Exclusion criteria

Exclusion criteria: 1. History of any ocular disease other than DED 2. Meibomian gland dysfunction 3. Contact lens use 4. Ocular trauma or surgeries 5. Presence of an uncontrolled systemic disease that could affect ocular surface condition 6. Punctual plugs 7. Used any eye drops other than artificial tears 8. Used any systemic medication that can cause dry eye 9. Pregnant

Design outcomes

Primary

MeasureTime frame
1. Basal tear secretion (baseline and every 20 minutes) – assessed by Schirmer score 2. Dry eye symptom (baseline and after 60 minutes): using the questionnaire (0, no symptoms; 1, mild symptoms; 2, moderate symptoms; 3, severe symptoms; and 4, very severe symptoms)

Secondary

MeasureTime frame
1. Cooling sensation (baseline and every 5 minutes) – assessed by visual analogue scale (VAS) (0 to 10) 2. Tear-film break up time (baseline and every 10 minutes) - the time before the defect of fluorescein dye appeared in the stained tear film was measured and recorded (measured TBUT 3 times and averaged) 3. Corneal sensitivity (baseline and every 20 minutes) – measured using the Cochet-Bonnet esthesiometer 4. Keratoepitheliopathy score (baseline and every 30 minutes) – after staining the cornea with fluorescein dye, the score was obtained by multiplying the stained area (0-3) by stained density (0-3) Area (0, no punctate staining; 1, area occupied less than 1/3 of the cornea; 2, area occupied 1/3 to 2/3 of the cornea; 3, area occupied greater than 2/3 of the cornea) Density (0, no punctate staining; 1, sparse density; 2, moderate density; 3, high density and the overlapped lesions) These outcomes were measured for 1 hour (60 minutes)

Countries

Korea, South

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 26, 2026